Showing results (11-20 of 838) with videos related to
Sort By:
Pageof 84
Experimental Hematology|June 19, 2012
Impact of lenalidomide on the functional properties of human mesenchymal stromal cellsManja Wobus, Gwendolin Benath, Ruben A Ferrer, et al.Seminars in Hematology|September 30, 2017
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitorsAnna Mies, Uwe PlatzbeckerBlood|May 10, 2013
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLNona Shayegi, Michael Kramer, Martin Bornhäuser, et al.Haematologica|June 24, 2009
Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cellsRebekka Wehner, Diana Wehrum, Martin Bornhäuser, et al.Blood Advances|November 13, 2019
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?Felicitas Thol, Uwe PlatzbeckerBest Practice & Research. Clinical Haematology|February 11, 2014
Allogeneic stem cell transplantation in MDS: how? When?Uwe Platzbecker, Ghulam MuftiDrugs|November 24, 2018
Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?Katja Sockel, Uwe PlatzbeckerCurrent Hematologic Malignancy Reports|October 5, 2013
When to transplant MDS, and what to do when transplant failsKatja Sockel, Uwe PlatzbeckerHematology/Oncology Clinics of North America|December 3, 2014
Transplants in myelodysplastic syndromesKatrin Wetzko, Uwe PlatzbeckerTransfusion|August 29, 2006
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myelomaFrank Kroschinsky, Kristina Hölig, Uwe Platzbecker, et al.Pageof 84